Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is ambitious when measured by our usual standards. As the designated Pharmalot groundskeeper, we plan to beautify the grounds. We also hope to make time to promenade with the official mascot, indulge our shortest person, and catch up on our reading (a book about spies awaits). And what about you? This is a fine time to make a vaccine appointment. Those of you who see that your cup is half full could plan a getaway for later this year. Or you could simply enjoy the great outdoors. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

AstraZeneca (AZN) has struggled to pull together the full data necessary to apply for U.S. approval of its Covid-19 shot, further delaying its efforts to secure a go-ahead from the Food and Drug Administration, The Wall Street Journal reports. The company said last month that it would apply for emergency use authorization for its vaccine by mid-April. It has recently told U.S. officials it might need until mid-May to finish its application for an FDA review.


The vaccine developed by AstraZeneca and the University of Oxford brought in $275 million in sales from about 68 million doses delivered in the first three months of this year, mostly from Europe, The New York Times tells us. It offers the clearest view to date of how much money is being brought in by one of the leading Covid-19 vaccines. AstraZeneca, which has pledged not to profit on its vaccine during the pandemic, has been selling the shot to governments for several dollars per dose, less expensive than the other leading vaccines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!